We are live on
!
Find out more
SCM
Suvretta Capital Management Portfolio holdings
AUM
$5.47B
1-Year Est. Return
131.34%
This Fund
S&P 500
This Quarter
Est. Return
+31.33%
1 Year Est. Return
+131.34%
3 Year Est. Return
+363.85%
5 Year Est. Return
+515.73%
10 Year Est. Return
+2,786.05%
AUM
$2.21B
AUM Growth
+$361M
(+20%)
Cap. Flow
-$69.2M
Cap. Flow
% of AUM
-3.13%
Top 10 Holdings %
Top 10 Hldgs %
47.06%
Holding
101
New
14
Increased
23
Reduced
22
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ultragenyx Pharmaceutical
RARE
|
+$56.1M |
| 2 |
TSMC
TSM
|
+$37M |
| 3 |
Goldman Sachs
GS
|
+$36.8M |
| 4 |
Apollo Global Management
APO
|
+$30.8M |
| 5 |
Ferguson
FERG
|
+$29.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$91M |
| 2 |
Advanced Micro Devices
AMD
|
+$42.8M |
| 3 |
Wynn Resorts
WYNN
|
+$42.5M |
| 4 |
NVIDIA
NVDA
|
+$38.5M |
| 5 |
Amazon
AMZN
|
+$35.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 70.28% |
| 2 | Technology | 8.34% |
| 3 | Consumer Discretionary | 5.97% |
| 4 | Communication Services | 5.67% |
| 5 | Industrials | 4.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Biohaven
BHVN
$2.27B
| $196M | 8.85% |
4,572,836
+567,236
| +14% | +$17.6M |
|
|
ACLX
2
DELISTED
Arcellx
ACLX
| $135M | 6.11% |
2,435,974
-433,993
| -15% | -$19.6M |
|
3
Royalty Pharma
RPRX
$26.8B
| $109M | 4.94% |
3,887,702
-208,043
| -5% | -$5.72M |
|
|
4
Ultragenyx Pharmaceutical
RARE
$1.47B
| $102M | 4.6% |
2,126,306
+1,446,847
| +213% | +$56.1M |
|
5
Kura Oncology
KURA
$1.14B
| $99.9M | 4.52% |
6,946,230
-389,615
| -5% | -$3.83M |
|
6
EyePoint Inc
EYPT
$398M
| $93.8M | 4.24% |
4,056,847
+564,700
| +16% | +$6.31M |
|
|
ITCI
7
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $83.5M | 3.78% |
1,165,948
-203,901
| -15% | -$11.7M |
|
8
Insmed
INSM
$27.3B
| $83.2M | 3.76% |
2,684,487
-761,847
| -22% | -$19.8M |
|
9
Meta Platforms (Facebook)
META
$1.57T
| $77.9M | 3.52% |
220,183
-60,462
| -22% | -$19.7M |
|
10
Microsoft
MSFT
$3.65T
| $60.9M | 2.75% |
161,924
-56,246
| -26% | -$20M |
|
|
MRNS
11
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $58.1M | 2.63% |
5,346,119
+141,177
| +3% | +$1.06M |
|
|
12
Amazon
AMZN
$2.77T
| $55.9M | 2.53% |
368,089
-251,380
| -41% | -$35.2M |
|
|
ETNB
13
DELISTED
89bio
ETNB
| $54.6M | 2.47% |
4,888,434
+2,194,030
| +81% | +$20.2M |
|
|
14
Apollo Global Management
APO
$79B
| $50.4M | 2.28% |
540,820
+348,920
| +182% | +$30.8M |
|
|
15
Advanced Micro Devices
AMD
$830B
| $49.2M | 2.22% |
333,468
-363,042
| -52% | -$42.8M |
|
16
GE Aerospace
GE
$351B
| $45.5M | 2.06% |
446,294
+6,530
| +1% | +$605K |
|
|
17
Goldman Sachs
GS
$302B
| $42.6M | 1.92% |
+110,310
| New | +$36.8M |
|
|
18
TSMC
TSM
$2.28T
| $40.4M | 1.83% |
+388,232
| New | +$37M |
|
19
Boston Scientific
BSX
$66B
| $40.1M | 1.81% |
694,101
+340,360
| +96% | +$18.2M |
|
|
TERN
20
DELISTED
Terns Pharmaceuticals
TERN
| $37.9M | 1.71% |
5,837,126
-204,784
| -3% | -$1.08M |
|
21
Fulcrum Therapeutics
FULC
$292M
| $37.3M | 1.68% |
5,518,881
-200,000
| -3% | -$887K |
|
22
Las Vegas Sands
LVS
$28.6B
| $36.3M | 1.64% |
738,163
+95,330
| +15% | +$4.51M |
|
|
23
Ferguson
FERG
$44.3B
| $34M | 1.54% |
+176,090
| New | +$29.7M |
|
24
Oracle
ORCL
$469B
| $34M | 1.54% |
322,050
+66,739
| +26% | +$7.28M |
|
|
KALV
25
DELISTED
KalVista Pharmaceuticals
KALV
| $32.9M | 1.49% |
2,684,005
+263,154
| +11% | +$2.39M |
|
Similar funds
NC
EI
AP
ENV
ACM
VCM
GCM
TPCW
Suvretta Capital Management's Q4 2023 Portfolio in Review
As of Q4 2023, Suvretta Capital Management held 101 positions worth $2.21B, up 20% from $1.85B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Suvretta Capital Management withdrew a net $69.2M in Q4 2023, closing 13 positions and reducing 22 holdings. Its most notable exit was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $91M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 65% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Suvretta Capital Management opened a new position in TSMC worth $40.4M.
- Suvretta Capital Management's largest Q4 2023 buy was TSMC: 388,232 shares worth $40.4M.
- Suvretta Capital Management added most to Ultragenyx Pharmaceutical in Q4 2023, an estimated $56.1M increase.
- Suvretta Capital Management's biggest Q4 2023 reduction was Advanced Micro Devices, cutting an estimated $42.8M.
- Suvretta Capital Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2023, selling an estimated $91M.
- Suvretta Capital Management's ten largest holdings make up 47% of its $2.21B portfolio in Q4 2023.
- Suvretta Capital Management opened 14 new positions and closed 13 in Q4 2023.
- Suvretta Capital Management's portfolio value rose 20% quarter-over-quarter to $2.21B.
Based on Suvretta Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.